No Data
Staidson (300204.SZ): The summary report of the Phase IIb clinical study for injectable STSP-0601 has been obtained.
Staidson (300204.SZ) announced that the company has obtained the IIb phase clinical trial approval for the injectable STSP-0601...
Main business income declined, Staidson is expected to report a loss of up to 0.15 billion in 2024 | Interpretations
① Staidson expects revenue in 2024 to decrease by 19.78%-1.95% year-on-year, with a net loss attributable to shareholders of 0.148 billion yuan-0.121 billion yuan, which is a narrowing compared to 2023. ② To integrate resources and reduce costs and increase efficiency, Staidson will deregister three loss-making subsidiaries in 2024.
Staidson (300204.SZ): Expected losses for the year 2024 are between 0.121 billion yuan and -0.148 billion yuan.
On January 15, Glorious Exchange announced that Staidson (300204.SZ) released its performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be a loss of 0.148 billion yuan to 0.121 billion yuan, compared to a loss of 0.399 billion yuan in the same period last year; the net income after deducting non-recurring gains and losses is expected to be a loss of 0.159 billion yuan to 0.130 billion yuan, down from a loss of 0.406 billion yuan in the same period last year; revenue is expected to be approximately 0.292 billion yuan to 0.357 billion yuan, which is a change of -19.78% to -1.95% compared to the same period last year; after deducting, revenue is expected to be approximately 0.292 billion yuan to 0.357 billion yuan, with a change of -19.78% compared to the same period last year.
Shu Taishen: 2024 Annual Results Forecast Announcement
Joinn Laboratories will provide Staidson Group with comprehensive pharmaceutical R&D services covering both non-clinical and clinical trial phases.
Joinn Laboratories (06127) announced that on December 20, 2024, the company entered into a framework agreement for Staidson's research and development services for 2025, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide the Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases in accordance with the 2025 Staidson research and development services framework agreement. Due to the long-term cooperation with the Staidson Group, we are able to further expand into the pharmaceutical contract research organization service market and enhance our brand reputation, the Director believes that the 2025 Staidson research and development services framework agreement is in line with the company's strategy.
JOINN Laboratories Partners With Staidson for 2025 R&D Services
No Data
